Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy

Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy

Severe thrombocytopenia (≤50×109 platelets/L) due to hematological malignancy and intensive chemotherapy is associated with an increased risk of clinically significant bleeding. Since the bleeding risk is not linked to the platelet count only, other hemostatic factors must be involved. We studied pl...

Full description

Bibliographic Details
Main Authors: Constance C. F. M. J. Baaten, Floor C. J. I. Moenen, Yvonne M. C. Henskens, Frauke Swieringa, Rick J. H. Wetzels, René van Oerle, Harry F. G. Heijnen, Hugo ten Cate, Graham P. Holloway, Erik A. M. Beckers, Johan W. M. Heemskerk, Paola E. J. van der Meijden
Format: Article
Language:English
Published: Ferrata Storti Foundation 2018-09-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/8596

Internet

https://haematologica.org/article/view/8596

Similar Items